Adverse events ( AEs ) observed in > 5 % of either the armodafinil 150 mg or placebo groups and more frequently with 150 mg armodafinil were diarrhea ( 9 % [ 17/198 ] vs 7 % [ 13/199 ] ) , and nausea ( 6 % [ 11/198 ] vs 5 % [ 9/199 ] ) , respectively .